Probiotic strains for pets
The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.
1. A method for producing a pet food, the method comprising:
providing a probiotic;
exposing the probiotic to a gastric juice;
providing a model of a pet small intestine;
introducing the probiotic and a pathogen into the model;
measuring the amount of an anti-pathogenic metabolite produced by the probiotic; and
adding the provided probiotic to an ingestible composition for pets in an amount sufficient to produce an effective anti-pathogenic metabolite,
wherein the probiotic is a bacterial strain selected from the group consisting of Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus johnsonii NCC 2777 (CNCM I-3852), Lactobacillus johnsonii NCC 2767 (CNCM I-3849), Lactobacillus johnsonii NCC 2774 (CNCM I-3850), and Lactobacillus salivarius NCC 2586 (CNCM I-3847).
2. The method of claim 1 , wherein the pet is a canine.
3. The method of claim 1 , wherein the pet food is dog food.
4. The method of claim 1 , wherein the provided probiotic produces an anti-pathogenic metabolite that lowers the pH of the gastrointestinal tract locally to a range of from about 4.5 to about 5.5.
5. The method of claim 1 , wherein the provided probiotic produces an anti-pathogenic metabolite that inhibits the growth of a pathogen present in the gastrointestinal tract, the pathogen selected from the group consisting of enterotoxigenic Escherichia coli, Escherichia coli, Salmonella typhimurium, Shigella dysenteriae and combinations thereof.
6. The method of claim 1 , wherein the pathogen introduced into the model is selected from the group consisting of enterotoxigenic Escherichia coli, Escherichia coli, Salmonella typhimurium, Shigella dyvsenteriae and combinations thereof.
7. The method of claim 1 , wherein the anti-pathogenic metabolite produced by the probiotic is selected from the group consisting of lactic acid, acetic acid, citric acid, pyruvic acid, hydrogen peroxide, and combinations thereof.
8. The method of claim 1 , wherein the provided probiotic produces lactic acid in an amount of from about 10 mM to about 90 mM.
9. The method of claim 1 , wherein the provided probiotic produces hydrogen peroxide in an amount of from about 0.1 mM to about 4.5 mM.
10. The method of claim 1 , wherein the provided probiotic is capable of surviving in a pH 2.6 environment for at least 10 minutes.
11. The method of claim 1 , wherein the provided probiotic is capable of surviving in a pH 3.4 environment for at least 60 minutes.
12. The method of claim 1 , wherein the provided probiotic is obtained from a fecal sample of a dog or a cat.